PL1771415T3 - Pochodne 2-(1H-indolilosulfanylo)-aryloaminy do stosowania w leczeniu zaburzeń afektywnych, ADHD i wysiłkowego nietrzymania moczu - Google Patents

Pochodne 2-(1H-indolilosulfanylo)-aryloaminy do stosowania w leczeniu zaburzeń afektywnych, ADHD i wysiłkowego nietrzymania moczu

Info

Publication number
PL1771415T3
PL1771415T3 PL05759183T PL05759183T PL1771415T3 PL 1771415 T3 PL1771415 T3 PL 1771415T3 PL 05759183 T PL05759183 T PL 05759183T PL 05759183 T PL05759183 T PL 05759183T PL 1771415 T3 PL1771415 T3 PL 1771415T3
Authority
PL
Poland
Prior art keywords
indolylsulfanyl
adhd
pain
treatment
urinary incontinence
Prior art date
Application number
PL05759183T
Other languages
English (en)
Inventor
Jan Kehler
Friedrich Kroll
Karsten Juhl
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PL1771415T3 publication Critical patent/PL1771415T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL05759183T 2004-07-16 2005-07-13 Pochodne 2-(1H-indolilosulfanylo)-aryloaminy do stosowania w leczeniu zaburzeń afektywnych, ADHD i wysiłkowego nietrzymania moczu PL1771415T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58855504P 2004-07-16 2004-07-16
DKPA200401121 2004-07-16
US69173605P 2005-06-17 2005-06-17
DKPA200500893 2005-06-17
PCT/DK2005/000491 WO2006007843A1 (en) 2004-07-16 2005-07-13 2-(1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence
EP05759183A EP1771415B1 (en) 2004-07-16 2005-07-13 2- (1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence

Publications (1)

Publication Number Publication Date
PL1771415T3 true PL1771415T3 (pl) 2009-06-30

Family

ID=39243745

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05759183T PL1771415T3 (pl) 2004-07-16 2005-07-13 Pochodne 2-(1H-indolilosulfanylo)-aryloaminy do stosowania w leczeniu zaburzeń afektywnych, ADHD i wysiłkowego nietrzymania moczu

Country Status (26)

Country Link
US (1) US7678800B2 (pl)
EP (1) EP1771415B1 (pl)
JP (1) JP4865710B2 (pl)
KR (1) KR20070036061A (pl)
CN (1) CN1972911A (pl)
AR (1) AR052308A1 (pl)
AT (1) ATE420071T1 (pl)
AU (1) AU2005263324A1 (pl)
BR (1) BRPI0512073A (pl)
CA (1) CA2570805C (pl)
CY (1) CY1108942T1 (pl)
DE (1) DE602005012272D1 (pl)
DK (1) DK1771415T3 (pl)
EA (1) EA011418B1 (pl)
ES (1) ES2317266T3 (pl)
HR (1) HRP20090112T3 (pl)
IL (1) IL179924A0 (pl)
MX (1) MXPA06015201A (pl)
NO (1) NO20066010L (pl)
PL (1) PL1771415T3 (pl)
PT (1) PT1771415E (pl)
RS (1) RS50804B (pl)
SI (1) SI1771415T1 (pl)
UA (1) UA82610C2 (pl)
WO (1) WO2006007843A1 (pl)
ZA (1) ZA200610162B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP5318757B2 (ja) 2006-06-16 2013-10-16 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
CA2729635A1 (en) * 2008-07-03 2010-01-07 Ananth Srinivasan Compounds and processes for production of radiopharmaceuticals
CA2910038A1 (en) * 2013-11-14 2015-05-21 California Institute Of Technology Accommodating intraocular lens
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CN108536644B (zh) * 2015-12-04 2022-04-12 格兰菲智能科技有限公司 由装置端推核心入队列的装置

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803143A (en) 1969-09-08 1974-04-09 Eisai Co Ltd 6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en) 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US4055665A (en) 1974-11-25 1977-10-25 Merck & Co., Inc. Treating arrythmia with phenylthioaralkylamines
US4056632A (en) 1975-07-21 1977-11-01 Burroughs Wellcome Co. 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0396827A1 (en) 1989-05-09 1990-11-14 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof
GB8912971D0 (en) 1989-06-06 1989-07-26 Wellcome Found Halogen substituted diphenylsulfides
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
DE69230803T2 (de) * 1991-11-25 2000-12-07 Pfizer Inc., New York 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5945425A (en) * 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US6048876A (en) 1995-01-23 2000-04-11 Suntory Limited Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor
DE907654T1 (de) 1995-11-06 1999-09-16 Gist-Brocades B.V. Verfahren zur de-esterifikation
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2188970T3 (es) 1996-08-27 2003-07-01 Wyeth Corp 4-aminoetoxiindoles, como agonistas d2 de dopamina y como ligandos de los receptores 5ht1a.
GB9725953D0 (en) 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
DE19756036A1 (de) * 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6333146B1 (en) * 1999-03-10 2001-12-25 Fuji Photo Film Co., Ltd. Methine compound and silver halide photographic material containing the same
MXPA01009915A (es) 1999-04-02 2003-08-20 Icos Corp Inhibidores de lfa-1 que se unen a los icam y usos de los mismos.
JP2002543173A (ja) 1999-04-30 2002-12-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア セロトニン輸送体のためのｓｐｅｃｔ画像化剤
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
AP2002002481A0 (en) 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
BR0016952A (pt) 1999-12-30 2002-10-08 Lundbeck & Co As H Compostos derivados de fenil-piperazina substituìdos, composição farmacêutica, uso e método
AU2152001A (en) 1999-12-30 2001-07-16 H. Lundbeck A/S Phenylpiperazinyl derivatives
EP1246817B1 (en) 1999-12-30 2004-06-23 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
US20020044914A1 (en) * 2000-02-29 2002-04-18 Dooley Thomas P. Inhibitors of melanocyte tyrosinase as topical skin lighteners
EP1283039A4 (en) * 2000-05-19 2007-05-30 Takeda Pharmaceutical INHIBITORS OF -SECRETASE
US6455738B1 (en) * 2000-07-13 2002-09-24 Rhodia Chimie Process for the sulfonation of an aromatic compound
US20030187023A1 (en) * 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
WO2002015910A1 (en) * 2000-08-18 2002-02-28 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
BR0113445A (pt) * 2000-09-01 2005-04-12 Fmc Corp Composto, composição, e, método para o controle de insetos
US6777446B2 (en) * 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
EP1193268A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
JP5049452B2 (ja) * 2000-10-06 2012-10-17 バイオコンパティブルズ ユーケー リミテッド 両性イオン重合体
US20020173524A1 (en) * 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
CN1222291C (zh) 2000-11-14 2005-10-12 默克专利股份有限公司 联合的5－ht1a激动剂和5－羟色胺再摄取抑制剂的新用途
AR035521A1 (es) * 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
PL367305A1 (pl) 2001-06-07 2005-02-21 F.Hoffmann-La Roche Ag Nowe pochodne indolu z powinowactwem do receptora5-HT6
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
JP2005509032A (ja) * 2001-11-14 2005-04-07 シェーリング　コーポレイション カンナビノイドレセプターリガンド
AU2002351747B2 (en) 2001-12-21 2008-06-05 H. Lundbeck A/S Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
US8048408B2 (en) * 2002-01-16 2011-11-01 Biocompatibles Uk Limited Polymer conjugates
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
CN1639175A (zh) * 2002-03-04 2005-07-13 独立行政法人科学技术振兴机构 新型膦酰胺化合物、其制造方法及用途
CA2480518C (en) * 2002-03-29 2016-07-19 Massachusetts Institute Of Technology Light emitting device including semiconductor nanocrystals
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
EP1539693B9 (en) * 2002-06-19 2008-10-08 Schering Corporation Cannabinoid receptor agonists
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
PT1587788E (pt) * 2002-09-17 2007-08-20 Hoffmann La Roche ''indoles 2,7-substituídos e a sua utilização como moduladores de 5-ht6''
NZ538047A (en) * 2002-09-17 2007-10-26 Hoffmann La Roche 2,4-substituted indoles and their use as 5-HT6 modulators
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040266732A1 (en) * 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
DE60309498T2 (de) * 2002-10-18 2007-08-30 F. Hoffmann-La Roche Ag 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
US20040137389A1 (en) * 2002-12-19 2004-07-15 Kouta Fukui Heat-developable light-sensitive material
NZ541234A (en) * 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
US7189501B2 (en) * 2002-12-27 2007-03-13 Fuji Photo Film Co., Ltd. Silver halide color photographic photosensitive material
DE10300098A1 (de) * 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
EP2267049A1 (en) * 2003-02-05 2010-12-29 Biocompatibles UK Limited Block copolymers
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP2258365B1 (en) * 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1671962A1 (en) * 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
US7229751B2 (en) * 2003-11-20 2007-06-12 Konica Minolta Medical & Graphic, Inc. Silver salt photothermographic dry imaging material and image forming method using the same
US20050250794A1 (en) * 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
ATE396970T1 (de) * 2003-12-23 2008-06-15 Lundbeck & Co As H 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
SE528250C2 (sv) * 2004-02-27 2006-10-03 Calignum Technologies Ab Komposition innefattande en initiator och ett förfarande för att behandla trä med kompositionen
JP4569142B2 (ja) * 2004-03-22 2010-10-27 コニカミノルタホールディングス株式会社 表示素子
JP4448730B2 (ja) * 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
US20090156471A1 (en) 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006098380A1 (ja) 2005-03-15 2006-09-21 Fujifilm Corporation 円盤状化合物を用いた表面処理法、表面処理用（潤滑）組成物及び表面処理された物品

Also Published As

Publication number Publication date
JP2008506640A (ja) 2008-03-06
ZA200610162B (en) 2008-06-25
AU2005263324A1 (en) 2006-01-26
AR052308A1 (es) 2007-03-14
JP4865710B2 (ja) 2012-02-01
CN1972911A (zh) 2007-05-30
NO20066010L (no) 2006-12-27
US20080027074A1 (en) 2008-01-31
ATE420071T1 (de) 2009-01-15
UA82610C2 (uk) 2008-04-25
MXPA06015201A (es) 2007-03-15
SI1771415T1 (sl) 2009-04-30
BRPI0512073A (pt) 2008-02-06
WO2006007843A1 (en) 2006-01-26
PT1771415E (pt) 2009-03-16
ES2317266T3 (es) 2009-04-16
CA2570805C (en) 2010-08-24
DK1771415T3 (da) 2009-02-23
EA200602180A1 (ru) 2007-04-27
EA011418B1 (ru) 2009-02-27
HRP20090112T3 (hr) 2009-03-31
CA2570805A1 (en) 2006-01-26
IL179924A0 (en) 2007-05-15
RS50804B (sr) 2010-08-31
EP1771415B1 (en) 2009-01-07
US7678800B2 (en) 2010-03-16
CY1108942T1 (el) 2014-07-02
EP1771415A1 (en) 2007-04-11
DE602005012272D1 (de) 2009-02-26
KR20070036061A (ko) 2007-04-02

Similar Documents

Publication Publication Date Title
PL1849773T3 (pl) Pochodne piperazyny do leczenia nietrzymania moczu i bólu
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
IL180078A0 (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
EP2073752A4 (en) IMPLANTABLE DEVICES FOR THE TREATMENT OF INCONTINENCE, AND METHODS OF USE
IL188922A0 (en) Benzoquinazoline derivatives and their use in treating bone disorders
PL372395A1 (pl) Zastosowanie inhibitorów cyklooksygenazy i środków antymuskarynowych do leczenia nietrzymania moczu
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
IL189578A0 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
SI1761266T1 (sl) Spojine, formulacije in postopki za zdravljenje ali preprečevanje vnetnih kožnih motenj
EP1761204A4 (en) IMPLANTABLE DEVICE FOR THE TREATMENT OF DISEASES AND METHODS OF USE
IL183557A0 (en) The use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome
EP1879578A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
IL179924A0 (en) 2 - (1h-indolylsulfanyl) - aryl amine derivatives for use in the treatment of affective disorders, pain adhd and stress urinary incontinence
IL176968A0 (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
IL205680A0 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
IL178827A0 (en) Use of reboxetine for the treatment of pain
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
EP1933853A4 (en) TREATMENT OF TISSUE DISTRACTION AND COMPOSITION FOR APPLYING THEREOF
NO20043614L (no) 2`-halogen-3`,5`-dialkoksyfen-1`-yl-imino-2-imidazolid in-derivater og anvendelse derav for behandling av urin-inkontinens
WO2008002544A3 (en) Unit dosage forms of temozolomide
TWI350753B (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
EP1879519A4 (en) IMPLANTABLE SLINGS FOR TREATING INCONTINENCE AND USE METHOD THEREFOR
ZA200803239B (en) Treatment of stress urinary incontinence and mixed urinary incontinence